Clinical Trial

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess how well-tolerated GSK's investigational varicella vaccine (VNS Vaccine) is, in comparison to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted on healthy children aged 12 to 15 months, and who have neither contracted varicella nor received a varicella vaccination.
Trial Details
NCT Number NCT06693895
Lead Sponsor GlaxoSmithKline
Conditions Chickenpox
Enrollment 750 participants
Start Date 2024-11-26
Primary Completion 2026-11-23 (estimated)
Study Completion 2026-11-23 (estimated)
Updated on ClinicalTrials.gov 2026-05-29